The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when
administered in combination with glucagon-like peptide (GLP-1) receptor agonist called
liraglutide in treatment-naïve healthy participants. The study will include 2 parts. The
study will last up to 16 and 22 weeks for part A and B, respectively which includes a
screening period of 6 weeks.